Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer

Abstract

Background In phase II studies, irinotecan is active in metastatic colorectal cancer, but the overall benefit has not been assessed in a randomised clinical trial. Methods Patients with proven metastatic colorectal cancer, which had progressed within 6 months of treatment with fluorouracil, were randomly assigned either 300-350 mg/m2 irinotecan every 3 weeks with supportive care or supportive care alone, in a 2:1 ratio. Findings 189 patients were allocated irinotecan and supportive care and 90 supportive care alone. The mean age of the participants was 58.8 years; 181 (65%) were men and 98 (35%) were women. WHO performance status was 0 in 79 (42%) patients, 1 in 77 (41%) patients, and 2 in 32 (17%) patients. Tumour-related symptoms were present in 134 (71%) patients and weight loss of more than 5% was seen in 15 (8%) patients. With a median follow-up of 13 months, the overall survival was significantly better in the irinotecan group (p=0.0001), with 36.2% 1-year survival in the irinotecan group versus 13.8% in the supportive-care group. The survival benefit, adjusted for prognostic factors in a multivariate analysis, remained significant (p=0.001). Survival without performance-status deterioration (p=0.0001), without weight loss of more than 5% (p=0.018), and pain-free survival (p=0.003) were significantly better in the patients given irinotecan. In a quality-of-life analysis, all significant differences, except on diarrhoea score, were in favour of the irinotecan group. Inte…

Overview

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(98)02309-5

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 18 references

Research works printed but not linked: 4

  1. Fages, 1997, Tumor response and stabilization rates are worthwhile surrogate endpoints in metastatic colorectal cancer. analysis of data in 455 5FU-resistant patients treated with CPT-11, Proc ASCO, 16, 288a
  2. Van Cutsem, 1997, Clinical benefit of irinotecan (CPT-11) in metastatic colorectal cancer (CRC) resistant to 5-FU, Proc ASCO, 16, 268a
  3. Kemeny, 1989, Prognostic variables in patients with hepatic metastases from colorectal cancer, Cancer, 63, 742, 10.1002/1097-0142(19890215)63:4<742::AID-CNCR2820630423>3.0.CO;2-T · doi:10.1002/1097-0142(19890215)63:4<742::aid-cncr2820630423>3.0.co;2-t
  4. Ross, 1996, Chemotherapy for colorectal cancer: relationship between toxicity and quality of life, Ann Oncol, 7, 34

Cited by

See all 1,259

Metadata

Authors
Cunningham, D., Pyrhönen, S., James, R. D., Punt, C. J., Hickish, T. F., Heikkila, R., Johannesen, T. B., Starkhammar, H., Topham, C. A., Awad, L., Jacques, C., & Herait, P.
Affiliations
  • Royal Marsden Hospital (GB)
  • Helsinki University Hospital (FI)
  • The Christie Hospital (GB)
  • Royal Bournemouth Hospital (GB)
  • Linköping University Hospital (SE)
Corresponding author
Cunningham, David
Venue
The Lancet
Publisher
Elsevier BV
Published
1998-10
Volume
352
Issue
9138
Pages
1413-1418
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W2096122707
Cited by
1,259
References
18
Citations by year
2026: 3 · 2025: 8 · 2024: 6 · 2023: 15 · 2022: 8 · 2021: 7 · 2020: 13 · 2019: 15 · 2018: 25 · 2017: 17 · 2016: 21 · 2015: 23 · 2014: 30 · 2013: 40 · 2012: 31
FWCI
28.78
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
  • Radboud Repository (Radboud University) (submittedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
Keywords
irinotecan, metastatic colorectal cancer, supportive care, overall survival, quality of life, weight loss, treatment side effects
MeSH terms
Irinotecan, Adult, Aged, Antimetabolites, Antineoplastic, Antineoplastic Agents, Phytogenic, Camptothecin, Female, Fluorouracil, Humans, Male, Middle Aged, Neoplasm Metastasis, Palliative Care, Probability, Quality of Life, Colorectal Neoplasms, Survival Analysis, Treatment Failure

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. https://app.cochat.ai/papers/10.1016/s0140-6736(98)02309-5
The paper
Cunningham, D., Pyrhönen, S., James, R. D., Punt, C. J., Hickish, T. F., Heikkila, R., Johannesen, T. B., Starkhammar, H., Topham, C. A., Awad, L., Jacques, C., & Herait, P. (1998). Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. The Lancet. https://doi.org/10.1016/s0140-6736(98)02309-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.